Bipolar disorder (BD) is a major psychiatric condition that commonly requires prophylactic and episodic treatment. There is important variability in the therapeutic response and side-effect profiles to currently available pharmacological agents. Pharmacogenetics have provided new hopes to develop more efficient treatment strategies tailored to the individual patient's needs. This review assesses nonsystematically studies using pharmacogenetic strategies in BD. Most of these studies have focused on patients selected according to lithium response, and more recently, a growing number of studies have been investigating genetic factors in mixed samples of patients classified according to response to antidepressant treatment. Although previous clinical and family studies support the use of pharmacogenetic strategies both to increase phenotype homogeneity as well as to identify genetic factors that may mediate response to treatment, most molecular studies carried out to date are still preliminary and in need of external validation. A major problem has been comparability between studies, in part, because of differences in the criteria used to define response. More attention should be paid to standardize the criteria for drug response definition.
INTRODUCTION
Bipolar disorder (BD), or manic-depressive illness, is a chronic and often severe psychiatric disorder that is characterized by manic and depressive episodes and affects approximately 1% of the general population.
1,2 Therefore, it is not surprising that BD imposes a hefty burden on society, ranking sixth worldwide among the top causes of years lived with disability. 3 For many years now, genetic-epidemiologic studies using family, twin and adoption designs have been consistently indicating that genetic factors play a role in the etiology of BD. 4 This support encouraged the undertaking of molecular research attempting to map and identify susceptibility genes for this disorder. However, molecular genetic studies of BD have produced a myriad of results from which consistent conclusions are difficult to draw.
Pharmacogenetic strategies have been around for many years, but have come to the forefront of research in the past 5-10 years with hopes that it would be possible to produce insight into genetic mechanisms involved in response to drugs and their side effects. However, in addition to hopes for individualized, that is, less empirically broad treatments of BD patients and more efficient prevention of the most serious side effects to pharmacological treatment, pharmacogenetics in BD have also been used to help refine the phenotype, or in other words, to reduce phenotypic heterogeneity. [5] [6] [7] BD is treated at both the prophylactic and episodic level. Prophylactic treatment attempts to prevent the occurrence of either depressive or manic episodes, and until recently, it has been carried out primarily with lithium (Li). Over the past 15 years, although, there has been a greater tendency to use anticonvulsants such as valproate (VPA) and carbamazepine (CBZ)-and more recently, lamotrigine, gabapentin and topiramate-instead of Li as primary prophylactic agents.
MOOD-STABILIZING DRUGS Lithium
Li is a metallic element, which was first discovered by August Arfwedson, a Swedish chemist, in 1818. Li has widespread occurrence in nature and is present in small amounts in plant and animal tissue, including the human organism. Only a small fraction of the Li produced is used for medical purposes. As a drug, Li is always used in the form of one of its salts, such as Li carbonate or Li citrate, the active form being solely the ionic Li þ component. 8 Li was first introduced into medicine in the 1840s for the treatment of bladder stones and gout. The therapeutic effects of Li in BD were initially observed in the late 19th century and more recently by John Cade in 1949. 9 However, not until Mogen Schou's series of trials during the 1950s and 1960s did the short-term and prophylactic efficacy of Li become accepted. 10 Although Li has been widely used in the treatment of BD, with approximately 70-80% of patients showing full or partial response, the exact molecular mechanism underlying Li's therapeutic actions still remains elusive.
Among the most important molecular targets initially proposed for Li's action are monoaminergic neurotransmitter systems or receptors. Focus then shifted to cellular transmembrane signal transduction pathways, particularly G proteins, adenylyl cyclases, protein kinase C and components of the phosphoinositide system. [11] [12] [13] [14] [15] The phosphoinositide pathway has been shown to be directly affected by Li through its inhibition of two key enzymes involved in the regeneration of free inositol in the cell. This was further enforced when Berridge et al originally proposed, more than a decade ago, that Li inhibits the dephosphorylation of inositol (1, 4, 5) phosphate at therapeutic concentrations, and thus depletes cells of free inositol. 16 Recent in vitro experiments further support this initial observation by demonstrating that a deletion of the gene that codes for prolyl oligopeptidase, which regulates inositol metabolism, induces resistance to treatment with Li and valproic acid in Dictyostelium.
17,18
Although Li is a clearly effective mood stabilizer, its effectiveness tends to vary depending on clinical presentation as well as side-effect profile. Weight gain, polyuria, tremor, cognitive dulling in some cases have diminished Li's attractiveness to many patients and clinicians and are among the most common causes of Li noncompliance, which has been estimated to range between 18 and 53%. In addition, adherence to medication becomes difficult during the maintenance phase of the illness. 19 Several clinical predictors have been found to be indicative of the treatment outcome. A number of studies demonstrated that the presence of comorbid disorders, especially substance abuse predicts a poorer response to Li treatment. [20] [21] [22] On the other hand, clinical predictors of good response to Li include typical symptomatology, absence of residual symptoms between episodes, polarity of the first episode and absence of comorbidity. [21] [22] [23] In addition, as discussed in detail below, family history of BD seems to predict Li response.
Family Studies
Over the last decade, numerous studies have suggested increased recurrence of BD in relatives of Li-responsive probands (Table 1 ). It had been already known that primary affective disorders tend to run in families, and thus, it was hypothesized that response to Li treatment could also be familial. 31, 36 In 1972, Mendlewicz carried out the first study suggesting that selecting families according to the proband's response to Li led to different patterns of familial aggregation. 24 He found a higher risk of BD in first-and seconddegree relatives of responders in comparison to nonresponders. Many other studies have been preformed since then. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Although not all of them agree, 33, 34, 39 most studies found results suggesting that selecting probands according to Li response increases phenotypic homogeneity and selects for families with increased loading for affective disorders, whereas families of nonresponders tend to have increased aggregation of other psychiatric conditions such as schizophrenia. [25] [26] [27] [28] [29] [30] [31] [32] More recently, Grof et al, 40 when comparing response to long-term Li treatment in BD relatives of Li responders to BD controls collected consecutively from an outpatient clinic, found substantial evidence suggesting that response to Li prophylaxis also clusters in families. These results are encouraging and are consistent with the hypothesis that Li response clusters in families independent of the increased familial loading for affective disorders and that this aggregation could be genetically mediated. Interestingly, Alda et al 30, 32 investigated the mode of inheritance of Li-responsive families in two independent samples of families selected using the same criteria and found similar evidence in both studies for an autosomal recessive mode of inheritance with sex-specific penetrances. In summary, family and clinical studies are consistent with the notion that response to Li may be genetically mediated and suggest that Li prophylaxis may help define a more homogeneous BD phenotype with less genetic heterogeneity.
Molecular Studies
Molecular studies attempting to identify genes that may mediate Li response have only recently started to emerge; a few of these studies are depicted in Box 1. As such, most findings are preliminary and often jeopardized by a number of methodological limitations. Our group recently completed a genome-wide scan looking at 378 markers in a sample of 31 families with Li-responsive probands that were assessed prospectively, and on whom response was based on an average of 12-year follow-up according to the criteria listed in Box 2. 41 Evidence for linkage was found with a locus on chromosome 15q14 (ACTC, LOD score ¼ 3.46, Pharmacogenetics and bipolar disorder F Mamdani et al locus-specific P-value ¼ 0.000014) and suggestive results were observed for another marker on chromosome 7q11.2 (D7S1816, LOD score ¼ 2.68, locus-specific Pvalue ¼ 0.00011). Other interesting findings were obtained with markers on chromosomes 6 and 22, namely, D6S1050 (LOD score ¼ 2.0, locus-specific P-value ¼ 0.00004) and D22S420 (LOD score ¼ 1.91). Analyses according to Li response, although limited by the lower amount of available information, suggested that the ch15q14 locus was more likely to be involved in the BD phenotype, whereas the ch7q11.2 locus in Li response. These results are currently being further investigated.
Ewald et al 42 carried out a haplotype-based study using Li responders from the Faroe Islands, an isolated population where most of the population descends from a small number of settlers. They investigated 30 markers on ch18 and found augmented increased haplotype sharing around ch18q23 in eight bipolar patients who had common ancestors dating back to approximately six generations. This finding is interesting because another group had previously published positive linkage findings in this region of ch18 43 in another isolated population (from Costa Rica), but for which information on treatment strategy/response was not reported. Li response in the eight bipolar patients from the Faroe Islands was assessed by the criteria proposed by Grof et al, 31 and thus, in this regard, their results should be comparable to those obtained by our group. Interestingly, we found some evidence for Li linkage to ch18 markers in unilineal families of Li responders, 44 and our results provided some support, albeit modest, to linkage with a locus on ch18q22.3, suggesting that this chromosomal region should be further explored from a pharmacogenetic viewpoint.
Morissette et al 7 carried out a genome-wide screen for linkage in BD with families from Quebec, which is a homogeneous population also with a well-characterized founder effect. Probands in this study are described as having been selected according to a positive response to Li treatment. However, the authors do not specify precisely how Li response was assessed. The results of this study put Nonresponders were considered to be those that were categorized as having medium and high morbidity while undergoing Li treatment. BD ¼ bipolar disorder; UP ¼ unipolar disorder; MD ¼ major depression; SA ¼ schizoaffective disorder.
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Lamotrigine A growing number of alternative treatments have been proposed as mood stabilizers, most of which are based on the use of anticonvulsant drugs. Lamotrigine is one such drug that has been increasingly used for prophylactic treatment of BD. Lamotrigine is thought to result in heightened mood and alertness, 45 and it has been proposed to be more effective in bipolar II than in bipolar I patients. Lamotrigine appears to have significant antidepressant properties, which may be greater than other mood stabilizers. 46 Recently, Passmore et al 37 conducted a family study with probands selected according to lamotrigine response. Most markedly, lamotrigine responders tended to present a more chronic fluctuating course of disease, as opposed to a more episodic course and demonstrated comorbidity with substance abuse. Their relatives also had a lower risk of BD and an increased risk of nonaffective disorders, panic disorder or panic attacks in particular. 37 When lamotrigine responders were compared to Li responders, differences were perceived with respect to disease progression and characteristics, as well as family history.
PATHWAYS INVOLVED IN LITHIUM RESPONSE
The elucidation of pathways involved in the response to Li helps to narrow down the number of candidate genes likely to be involved in the etiology of Li-responsive BD. There are several pathways that have been proposed as possibly being inhibited by Li, subsequently causing downstream changes that may eventually lead to alterations in gene expression ( Figure 1) .
The phosphoinositide pathway has been one of the major focal points for the investigation of Li's mode of action. It has been postulated that the effects of Li are transduced via the G-protein-coupled phospholipase C (PLC) formation of inositol-1, 4, 5-triphosphate (IP 3 ) and diacylglycerol (DAG) from phosphatidylinositol-4, 5-bisphosphate (PIP 2 ). There are two enzymes that undergo Li-induced inhibition: inositol monophosphatase (IMPA) and inositol polyphosphate 1-polyphosphatase (INPP1). It is this inhibition that is the central tenet of the 'inositol depletion hypothesis' proposed by Berridge et al. 16 The inhibition of IMPA and INPP1 by Li causes a reduction in the amount of free inositol available for the regeneration of PIP 2 ; thus, consequently diminishing the cellular response to IP 3 and DAG. Now with the finding of a possible link between prolyl oligopeptidase and commonly used bipolar mood stabilizers, the inositol depletion hypothesis can be extended to explain the mechanisms of action of VPA and CBZ. Thus, it is possible This is a description of the criteria developed by Paul Grof et al, 31 which has been used by this group and others to diagnose BD patients as excellent Li responders. The eventual aim for those working in the field of psychiatric pharmacogenetics would be to adopt or develop common criteria for drug response, not only for Li but also for other common antibipolar drugs.
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It had been proposed by Klein and Melton 47 that the effects of Li on development and cell survival are due to its inhibition of glycogen synthase kinase 3b (GSK3b). It appears as though Li acts in the same manner as the Wnt pathway to induce inhibition of GSK3b. 48 The inhibition of GSK3b results in the translocation of b-catenin to the nucleus where it then becomes part of transcription complexes that induce the activation of components involved in cell survival. 49 GSK3b has also been linked to the modulation of several other transcription factors, such as, Myc, CREB and AP-1. 50 Using cell lines, Chen et al 51 were able to observe an increase in b-catenin levels following VPA administration. This finding was confirmed by Phiel et al 52 and they were able to correlate the inhibition of histone deacetylase, a regulator of transcription, by VPA with an increase in the expression of b-catenin. No effect of CBZ on this pathway has been reported. 53 GSK3b has been linked to several signaling pathways, and thus it can be inferred that the inhibition of this protein by Li will have a multitude of possible effects.
Another protein that has been recently linked to Li action is the myristoylated alanine-rich C-kinase substrate (MARCKS). MARCKS is phosphorylated following the activation of PKC and is involved in the neuroplasticity of neurons. Li has been shown to produce a decrease in MARCKS protein expression in the brain and this is hypothesized to occur in relation to the concentration of myoinositol and the activation of the phosphoinositide pathway. 54 These pathways are but a few of the ones on which evidence suggests a possible relation to Li's mode of action in the cell. It is possible that these pathways work in unison to produce Li-induced changes in the brain, and thus bring to the forefront the likelihood of a collection of genes being responsible for the positive effects Li incurs in treating BD. However, in spite of the evidence amassed so far, the candidate genes explored have been relatively few and there has been a bias towards studying components of neurotransmitter systems.
POPULATION STUDIES
Gene variation studies have typically focused on loci coding for components of the systems hypothesized to be possible targets for Li's action. However, in general, these studies have been carried out in samples that lack sufficient power and have tested single polymorphisms, by and large of uncertain functional value. In addition, different groups have used different criteria to define response, making direct comparisons difficult to make. Table 2 lists most of the association studies carried out to date.
The group of Serretti and co-workers has published a number of association studies investigating candidate genes that code for components of neurotransmitter systems and other related pathways in Li responders and nonresponders. This group defined response to Li based on a calculation determining the difference between pre-Li and on-Li episode frequency. The genes investigated included COMT, MAOA; G-protein b3 subunit (GNB3), 74 DRD3, 61 HTR1A, HTR2A, HTR2C; 69 and DRD2, DRD4 and GABRA1. 65 Their results suggest an association between homozygosity for the short allele of the promoter variant in the serotonin transporter gene (5-HTTLPR) and nonresponse to Li treatment. 73 On the other hand, Del Zompo et al 62 produced conflicting results as they found an association with the longer allele of this polymorphism and nonresponse to Li treatment in a sample of 67 BD patients of the same origin. Serretti et al 66 also reported a trend towards association between TPH variants and decreased clinical response to Li (for the TPH*A/A genotype). However, with the emergence of new evidence Figure 1 Pathways involved in Li, VPA and CBZ response; focus on the phosphoinositide and GSK-3b pathways. Upon ligand binding to a seven transmembrane G-protein-coupled receptor, there is the conversion of GTP to GDP following the dissociation of the a, b and c subunits. This results in the activation of second messengers: IP3 and DAG through PLC activation. Li, VPA and CBZ have been shown to inhibit key enzymes in the phosphoinositide pathway, which are responsible for the regeneration of free inositol in the cellL: IMPA and INPP1. Li has also been shown to inhibit GSK-3b, thus mimicking the inhibition of GSK-3b through the WNT pathway. Liinduced inhibition results in decreased degradation and translocation of b-cantenin to the nucleus where it regulates transcription factors. Asimilar effect is shown by VPA, but VPA increases b-catenin in the cell by inhibiting HDAC resulting in an increase of transcription or translation. PLC, phospholipase C; PKC, protein kinase C; DAG, diacyl glycerol; IP3, inositol-1, 4, 5-triphosphate; PIP2, phosphoinositide-4, 5-bisphosphate; PI, phosphoinositide; IMPA, inositol monophosphatase; INPP, inositol polyphosphate 1-phosphatase; FRZ, frizzled protein; DSH, disheveled protein; GSK3b, glycogen synthase 3b; HDAC, histone deacetylase.
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suggesting that there is a second TPH gene (TPH2), which seems to be the only variant expressed in the brain, 75 the results found with the previously studied polymorphism will need to be reinterpreted, and the studies will need to be repeated with the novel TPH gene.
Several observations strongly correlate the action of Li on PLC through the phosphoinositide pathway. 56, [59] [60] [61] [62] 71, 72 We reported evidence suggesting an association and mild evidence for linkage in unilineal families with an intronic locus on the gene coding for PLC-g1. 59 This locus was reexamined by Løvlie et al, 72 with inconclusive results. The polymorphism found previously in the PLCG1 gene was not known to be functional, so an investigation was carried out to locate other markers in the coding region through singlestrand conformational polymorphism analysis. 71 However, none of these potentially functional variants were differentially distributed when comparing 133 excellent Li responders and 99 controls, suggesting that our previous results were not the result of linkage disequilibrium with these variants. Further work is still needed to have conclusive results with regard to the potential role of PLCG1 in BD responsive to Li.
Other genes involved in the PLC signaling system and implicated in the recycling of inositol were also subject of thorough investigation. Steen and co-workers have characterized the genomic structure of two important genes: one coding for IMPA located on ch8q21 76 and the second encoding INPP1 on ch2q32 and tested for possible association with Li response. IMPA was a particularly interesting candidate due to its inhibition by Li and because it has two closely homologous genes, one of which, IMPA2, 77 is located on ch 18p11.2, in a region where linkage was initially reported on ch18 by Berrettini et al 78 and partially confirmed by our group. Steen et al 56 carried out an investigation to identify genetic variations that lead to various isoforms of IMPA in patients with BD. Their study was carried out using 21 patients with BD1; seven of which were Li responders, seven nonresponders and seven whose response was unknown vs 20 healthy controls. However, no genetic variants were found that would lead to altered IMPA functioning when comparing cases and controls. They also investigated four polymorphisms located in INPP1. 60 Four were found from which only one led to an amino-acid change, while the remaining three were silent SNPs. Of the silent variants, the C973A polymorphism was differently distributed between groups when Li-treated cases in their Norwegian sample were classified according to response, with the C973A allele present at a greater frequency in 
ANTIDEPRESSANTS
Studies investigating response to treatment for episodes are relatively easier to carry out than studies investigating prophylactic treatment, which often require long follow ups. As a result, there have been an increasing number of studies investigating patients selected according to response to antidepressants ( Table 3 ). The majority of these studies used mixed samples of BD and unipolar depression, thus posing some methodological difficulties to interpret results in the context of disease polarity. Nevertheless, given that many of the neurobiological processes underlying a depression episode may be common to both unipolar and bipolar depression, these studies are also relevant to this review. There is evidence that the response to antidepressant treatment is associated with the integrity of the signal transduction pathways that regulate cellular responses by transmitting signals from receptors to effector proteins. 86 G proteins are key elements of these pathways and both direct and indirect evidence of G-protein alterations in mood disorders have been reported. 87 In 2000, Zill et al published association data suggesting the involvement of a polymorphism in the gene coding for the GNB3 in antidepressant response. They investigated a C825T polymorphism in exon 10 of this gene, which is thought to be biologically functional, where the 825T allele codes for an in-frame deletion leading to a loss of 41 amino acids and one WD repeat domain of the protein. Their results suggested evidence of association between the 825T allele and depression, whereas homozygosity of the 825T allele was associated with a better response to antidepressant treatment when various classes of pharmacological and nonpharmacological treatments were considered. 79 However promising, these findings have to be further investigated and replicated, as independent studies thus far provided conflicting results. [83] [84] [85] [86] 88 Serretti et al 80, 81 carried out several investigations examining the TPH1 gene A218C variant in patient samples that had been treated with either paroxetine or fluvoxamine with or without pindolol augmentation. In both sample groups, MD and BD patients, it was found that those patients having the genotype homozygous or heterozygous for the TPH*A allele exhibited a poorer response to antidepressant treatment. On the other hand, patients taking paroxetine or fluvoxamine in combination with pindolol did not exhibit poor response associated with these genotypes. As mentioned previously, recent results suggest the existence of a second TPH gene (TPH2), which seems to code for a TPH isoform that appears to be primarily the TPH expressed in the brain. 75 Therefore, the results found by Serretti et al provide incentive to search for variants in the TPH2 gene that may produce significant association with antidepressant response in both MD and BD. Cusin et al 89 performed a similar study investigating the association between SSRI response and polymorphisms in MAOA and 5HT-2A genes in a sample of 248 MD and 195 BD patients; however, no association was found.
There have been suggestions that patterns of response to antidepressant could be familial. 90, 91 Smeraldi and coworkers have been further exploring this claim, through investigation of responders to fluvoxamine. They have published on familial aggregation and concordance of 45 mood disorder patient responders to fluvoxamine in two separate major depressive episodes and one of their firstdegree relatives; 92 of the probands, 16 were bipolars. More than half of the probands (67%) were concordant for response to fluvoxamine and relatives of concordant pairs had a higher risk of being diagnosed with BD.
The same group has recruited a large sample of 171 Italian families chosen according to fluvoxamine response for the purpose of segregation analyses. 6 They found evidence of an autosomal dominant mode of inheritance among the The data collected up to this point on fluvoxamine response are encouraging and leads one to believe that the selection of subjects who are responsive to this pharmacological treatment may increase genetic loading. However, questions such as how reproducible these findings are and how specific to fluvoxamine response, as opposed to pointing to common genetic pathways that may be common to other SSRIs or even other antidepressants, remain to be addressed.
Treating depression in BD patients is not a simple task due to the high instance of antidepressant-induced mania, and thus poses a challenge at the clinical level. The serotonin transporter (5-HTT) is the target of several of the antidepressants used in the treatment of BD. The 5-HTT gene, SLC6A4, located on chromosome 17, has two commonly studied polymorphisms: a promoter insertion/deletion and an intronic variable number of tandem repeat. Investigating 27 patients with antidepressant-induced mania and 29 bipolar patients with a negative history of antidepressantinduced manic switches, Mundo et al 82 have recently suggested that the short variant of the promoter polymorphism is associated with risk for development of antidepressant-induced mania. These results have to be confirmed in an independent and larger sample.
As mentioned previously, antidepressant response in MD has been better characterized than in BD, even though many of the articles reviewed have been carried out using mixed samples. Thus, it is difficult to classify positive results appropriately to either MD or BD. This brings forth the necessity to carry out more studies, if not with only BD samples, with mixed samples having a higher percentage of BD patients. By carrying out additional studies, it would be possible to enhance current knowledge between the molecular and clinical relationship in the pathophysiology of antidepressant-responsive BD.
DISCUSSION
Pharmacogenetic studies are becoming an increasingly popular method of investigation into the mechanisms of drug response for many diseases including those in psychiatry. An understanding of the genes involved in response has many advantages for the individualization of treatment to target-specific genetic alterations characteristic of each patient or sample population.
The studies included in this review fall broadly into two different categories or more specifically: (a) studies that were using a pharmacogenetic strategy primarily to help narrow down the bipolar phenotype and, as such, help reduce genetic heterogeneity in the identification of genetic factors underlying BD. These studies were primarily carried out comparing Li responders to normal controls. (b) Studies that were aiming at the identification of genetic vulnerability factors that may more directly be involved in treatment response. These factors may or may not be involved in the genetic vulnerability to BD. These studies typically compared responders against nonresponders to treatment.
Psychiatric pharmacogenetic studies are still in the early stages and have still much to evolve. The majority of the studies performed to date investigated samples of Li responders, and there are practically no studies looking at responders/nonresponders to other mood stabilizers, such as VPA, CBZ or other newer drugs. It would be important to have samples treated with mood stabilizers other than Li collected, so as to explore common genetic pathways that may mediate response to these agents. However, these studies are likely to be operationally challenging given the long-term follow-up required to define response to mood stabilizers (because of the expected periods of interepisode euthymia that are part of natural history of the disorder) and the association of several prophylactic agents, which nowadays is a common practice.
As for genetic studies of the psychiatric phenotype, pharmacogenetic studies of these conditions are also subject to several methodological problems and limitations. There has been a lack of reproducibility between the studies carried out so far. This may be related to several factors. Among these is the diverse criteria used by different studies in the definition of drug response. Accordingly, if the criteria used to define response are not comparable, then results cannot be directly compared between these studies. This is an important problem that should be kept in mind when designing new studies. It would be interesting that international agencies such as The International Society of Pharmacogenomics develop a set of recommended criteria that could help guide researchers when designing new studies.
Difficulties in pharmacogenetic studies in BD also arise from the complex nature of this disorder. Problems such as definition of the psychiatric phenotype, sample size investigated and population stratification are issues that are as likely to affect genetic and pharmacogenetic studies of BD. For instance, low power associated to the typically small sample sizes used in pharmacogenetic studies of BD to date has been a major problem. Another limitation of pharmacogenetic studies in BD is that most of the molecular studies have used association designs. Other approaches, such as family-based genome-wide scans, association mapping and expression studies using microarrays should also be implemented.
CONCLUSION
Despite the modest number of psychiatric pharmacogenetic studies performed using BD samples, the results obtained so far provide hope for additional investigation in this area. Although we are far from reaching the goal of individualizing treatment according to genetic makeup, the data reviewed here are encouraging and suggest that this may be eventually possible. However, studies should improve methodological quality and more attention should be paid to standardize the criteria to define drug response. 
